Black Rock Inc. Immunome Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Immunome Inc. stock. As of the latest transaction made, Black Rock Inc. holds 829,013 shares of IMNM stock, worth $12.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

829,013

Previous 390,636 112.22%

Holding current value

$12.4 Million

Previous $4.18 Million 389.59%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$11.01 - $27.34 $4.83 Million - $12 Million	438,377 Added 112.22%	829,013 $20.5 Million
Q4 2023 Feb 13, 2024	BUY	$7.3 - $10.73 $2.54 Million - $3.74 Million	348,107 Added 818.52%	390,636 $4.18 Million
Q3 2023 Nov 13, 2023	SELL	$6.17 - $9.16 $4,831 - $7,172	-783 Reduced 1.81%	42,529 $355,000
Q2 2023 Aug 11, 2023	BUY	$4.7 - $7.91 $8,333 - $14,024	1,773 Added 4.27%	43,312 $342,000
Q1 2023 May 12, 2023	SELL	$3.26 - $5.69 $1,398 - $2,441	-429 Reduced 1.02%	41,539 $207,000

Q4 2022 Feb 13, 2023	BUY	$2.21 - $4.85 $1,140 - $2,502	516 Added 1.24%	41,968 $92,000
Q3 2022 Nov 14, 2022	BUY	$3.39 - $6.14 $7,596 - $13,759	2,241 Added 5.72%	41,452 $183,000
Q2 2022 Aug 12, 2022	SELL	$2.24 - $5.79 $799 - $2,067	-357 Reduced 0.9%	39,211 $126,000
Q1 2022 May 12, 2022	SELL	$3.88 - $13.99 $4,155 - $14,983	-1,071 Reduced 2.64%	39,568 $224,000
Q4 2021 Feb 10, 2022	BUY	$12.96 - $23.44 $1,697 - $3,070	131 Added 0.32%	40,639 $527,000
Q3 2021 Nov 09, 2021	BUY	$12.5 - $27.76 $220,275 - $489,186	17,622 Added 77.0%	40,508 $986,000
Q2 2021 Aug 11, 2021	BUY	$16.33 - $32.33 $373,728 - $739,904	22,886 New	22,886 $396,000

Others Institutions Holding IMNM

# of Institutions

106

Shares Held

32.1M

Call Options Held

46.1K

Put Options Held

32.5K

View Full List

About Immunome Inc.

Ticker IMNM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,127,400
Market Cap $181M
Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...

More about IMNM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account